Nick Leschly bluebird bio CEO Rating

bluebird bio CEO Nick Leschly Bio

Mr. Nick Leschly has been the Chief Executive Officer and President at bluebird bio, Inc. (alternate name Genetix Pharmaceuticals Inc.) since September 2010. Mr. Leschly served as Interim President at bluebird bio, Inc. until September 2010. He was a Partner at Third Rock Ventures, LLC since 2007. He served as the Chief Business Officer of Agios Pharmaceuticals, Inc. Prior to joining Third Rock, he was the Product and Alliance Leader for Millennium Pharmaceuticals, Inc., and was the Product Leader for VELCADE???, managing a S100M+ global development plan. Mr. Leschly founded and served as the Chief Financial Officer of MedXtend Corporation. He joined Third Rock Ventures in 2007 as a Founding Member and played an integral role in the overall formation, development and business strategy of several of Third Rock's portfolio companies, including Agios Pharmaceuticals (AGIO), Inc. as well as identifying and evaluating new investments. He worked at Accenture Consulting, where he focused on the pharmaceutical industry. Mr. Leschly has been a Director of bluebird bio, Inc. since March 2010. He has been an Independent Director at Synlogic, Inc. since March 2016. Mr. Leschly served as Director of Edimer Pharmaceuticals Inc. He is the Founder and Chairman of The CAVU foundation. He is a Board Member of the Biotechnology Innovation Organization (BIO). Mr. Leschly holds a BS in Molecular Biology from Princeton University and an MBA from Wharton Business School.

bluebird bio CEO Nick Leschly At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at bluebird bio.

Based on 7 ratings, Nick Leschly ranks right below ImmunoGen's CEO, Mark Enyedy.

Overall, the CEO score has remained stable over the last 90 days.